Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta

Scandinavian Journal of Rheumatology

Volumn 34, Issue 6, 2005, Pages 485-488

  Strueby, L ^a   Nair, B ^a   Kirk, A ^a   Taylor Gjevre, R M ^a,b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b ROYAL UNIVERSITY HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; IBUPROFEN; LEVOTHYROXINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PREDNISONE; REPAGLINIDE;

ADULT; ARTHRITIS; AUTOIMMUNE DISEASE; BURSITIS; CASE REPORT; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPOTHYROIDISM; INFLAMMATORY DISEASE; INJECTION SITE REACTION; MONARTHRITIS; MULTIPLE SCLEROSIS; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; REVIEW; TEMPOROMANDIBULAR JOINT DISORDER; TREATMENT DURATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; ARTHRITIS; BURSITIS; FEMALE; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; THYROIDITIS, AUTOIMMUNE; TREATMENT OUTCOME;

EID: 30344462342     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740510026805     Document Type: Review

References (21)

1. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996;25:283-91.
2. Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991;115:178-83.
3. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 2000;43:1431-42.
4. PRISMS (prevention of relapses and disability by interferon-beta-1a subcutaneously in multiple sclerosis) Study Group, and University of British Columbia MS/MRI Analysis Group. PRISMS-4: long term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628-36.
5. Monzani F, Meucci G, Caraccio N, Saviozzi M, Casolaro A, Moscato G, et al. Discordant effect of IFN-beta1a therapy on anti-IFN antibodies and thyroid disease development in patients with multiple sclerosis. J Interferon Cytokine Res 2002;22:773-81.
6. Durelli L, Bongioanni MR, Ferrero B, Oggero A, Marzano A, Rizzetto M. Interferon treatment for multiple sclerosis: autoimmune complications may be lethal. Neurology 1998;50:570-1.
7. Nousari HC, Kimyai-Asadi A, Tausk FA. Subacute cutaneous lupus erythematosus associated with interferon beta-1A. Lancet 1998;352:1825-6.
8. Blake G, Murphy S. Onset of myasthenia gravis in a patient with multiple sclerosis during interferon-1B treatment. Neurology 1997;49:1747-8.
9. Noronha A, Toscas A, Jensen MA. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol 1993;46:145-53.
10. Tak PP. IFN-beta in rheumatoid arthritis. Frontiers Biosci 2004;9:3242-7.
11. Okada K, Kuroda E, Yoshida Y, Yamashita U, Suzumura A, Tsuji S. Effects of interferon-β on the cytokine production of astrocytes. J Neuroimmunol 2005;159:48-54.
12. Pilling D, Akbar AN, Girdlestone J, Orteu CH, Borthwick NJ, Amft N, et al. Interferon-beta mediates stromal cell rescue of T cells from apoptosis. Eur J Immunol 1999;29:1041-50.
13. Jabaily JA, Thompson JS. Effects of interferon beta-1B in rheumatoid arthritis: a case report. Arthritis Rheum 1997;40:1370.
14. Van Holten J, Reedquist K, Sattonet-Roche P, Smeets TJ, Plater-Zyberk C, Vervoordeldonk MJ, Tak PP. Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther 2004;6:R239-49.
15. Tak PP, 't Hart BA, Krann MC, Jonker M, Smeets TJM, Breedveld FC. The effects of interferon beta treatment on arthritis. Rheumatology 1999;38:362-9.
16. Genovese MC, Chakravarty EF, Krishnan E, Moreland LW. A randomized, controlled trial of interferon-beta-1a (Avonex®) in patients with rheumatoid arthritis: a pilot study. Arthritis Res Ther 2004;6:R73-7.
17. Van Holten J, Pavelka K, Vencovsky J, Stahl H, Rozman B, Genovese M, et al. A multicentre, randomized, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis. Ann Rheum Dis 2005;64:64-9.
18. Alsalameh S, Manger B, Kern P, Kalden J. New onset of rheumatoid arthritis during interferon beta-1B treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson. Arthritis Rheum 1998;41:754.
19. Russo R, Tenembaum S, Moreno MJ, Battagliotti C. Interferon beta-1A induced juvenile chronic arthritis in a genetically predisposed young patient with multiple sclerosis: comment on the case report by Levesque et al. Arthritis Rheum 2000;43:1190.
20. Altintas A, Alici Y, Melikoglu M, Siva A. Arthritis during interferon beta-1B treatment in multiple sclerosis. Multiple Sclerosis 2002;8:534-6.
21. Karow AC, Braun J, Marx P, Stangel M. Remission of a CNS inflammatory disease accompanied by newly developed ANA and arthropathy during treatment with INF-beta. J Neurol 2002;249:1121-2.